|
|
Previous Article | Table of Contents | Next Article 
Blood, 1 July 2002, Vol. 100, No. 1, pp. 148-152
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Thrombin functions during tissue factor-induced blood
coagulation
Kathleen E. Brummel,
Sara
G. Paradis,
Saulius Butenas, and
Kenneth G. Mann
From the Department of Biochemistry, University of
Vermont, College of Medicine, Burlington, VT.
Tissue factor-induced blood coagulation was studied in 20 individuals, for varying periods of time during 54 months, in contact pathway-inhibited whole blood at 37°C and evaluated in terms of the
activation of various substrates. After quenching over time with
inhibitors, the soluble phases were analyzed for thrombin-antithrombin III (TAT) complex formation, prothrombin fragments, platelet activation (osteonectin release), factor Va generation, fibrinopeptide (FP) A and
FPB release, and factor XIII activation. TAT complex formation, for 35 experiments, showed an initiation phase (up to 4.6 ± 0.6 minutes) in
which thrombin was generated at an average rate of 0.93 ± 0.3 nM/min
catalyzed by about 1.3 pM prothrombinase yielding approximately 26 nM
thrombin. During a subsequent propagation phase, thrombin was generated
at a rate of 83.9 ± 3.8 nM/min by about 120 pM prothrombinase,
reaching ultimate levels of 851 ± 53 nM. Clot time, determined
subjectively, occurred at 4.7 ± 0.2 minutes and correlated with the
inception of the propagation phase. The thrombin concentrations
associated with the transitions to rapid product formation are
510 ± 180 pM for platelet activation (1.9 ± 0.2 minutes),
840 ± 280 pM for factor XIII activation and factor Va generation
(2.2 ± 0.6 minutes), 1.3 ± 0.4 nM for FPA release (2.5 ± 0.7
minutes), 1.7 ± 0.5 nM for FPB release and prethrombin 2 (2.8 ± 0.8 minutes), 7.0 ± 2.2 nM for thrombin B chain
(3.6 ± 0.2 minutes), and 26 ± 6.2 nM for the propagation phase of
TAT formation (4.6 ± 0.6 minutes). These results illustrate that the
initial activation of thrombin substrates occurs during the initiation
phase at less than 2 nM thrombin (0.2%). Most thrombin (96%) is
formed well after clotting occurs.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Letter in Blood Online:
-
Factor XIII activation by thrombin depends on FXIIIVal34Leu genotype
- Verena Schroeder, Hans P. Kohler, Kathleen E. Brummel, and Kenneth G. Mann
Blood 2003 101: 371.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
F. Van de Werf
New antithrombotic agents: are they needed and what can they offer to patients with a non-ST-elevation acute coronary syndrome?
Eur. Heart J.,
July 2, 2009;
30(14):
1695 - 1702.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Undas, K. Szuldrzynski, K. E. Brummel-Ziedins, W. Tracz, K. Zmudka, and K. G. Mann
Systemic blood coagulation activation in acute coronary syndromes
Blood,
February 26, 2009;
113(9):
2070 - 2078.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Kamath and S. Krishnaswamy
Fate of Membrane-bound Reactants and Products during the Activation of Human Prothrombin by Prothrombinase
J. Biol. Chem.,
October 31, 2008;
283(44):
30164 - 30173.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Orfeo, K. E. Brummel-Ziedins, M. Gissel, S. Butenas, and K. G. Mann
The Nature of the Stable Blood Clot Procoagulant Activities
J. Biol. Chem.,
April 11, 2008;
283(15):
9776 - 9786.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Gurbel, R. C. Becker, K. G. Mann, S. R. Steinhubl, and A. D. Michelson
Platelet Function Monitoring in Patients With Coronary Artery Disease
J. Am. Coll. Cardiol.,
November 6, 2007;
50(19):
1822 - 1834.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Mittermayr, W. Streif, T. Haas, D. Fries, C. Velik-Salchner, A. Klingler, E. Oswald, C. Bach, M. Schnapka-Koepf, and P. Innerhofer
Hemostatic Changes After Crystalloid or Colloid Fluid Administration During Major Orthopedic Surgery: The Role of Fibrinogen Administration
Anesth. Analg.,
October 1, 2007;
105(4):
905 - 917.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Tanaka, F. Szlam, H. Y. Sun, T. Taketomi, and J. H. Levy
Thrombin Generation Assay and Viscoelastic Coagulation Monitors Demonstrate Differences in the Mode of Thrombin Inhibition Between Unfractionated Heparin and Bivalirudin
Anesth. Analg.,
October 1, 2007;
105(4):
933 - 939.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.S. Vieira, R.A. Ferriani, A.A. Garcia, M.C. Pintao, G.D. Azevedo, M.K.O. Gomes, and M.F. Silva-de-Sa
Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade
Hum. Reprod.,
August 1, 2007;
22(8):
2196 - 2201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T J Coats, E Brazil, M Heron, and P K MacCallum
Impairment of coagulation by commonly used resuscitation fluids in human volunteers.
Emerg. Med. J.,
November 1, 2006;
23(11):
846 - 849.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T J Coats, E Brazil, and M Heron
The effects of commonly used resuscitation fluids on whole blood coagulation.
Emerg. Med. J.,
July 1, 2006;
23(7):
546 - 549.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Chao
Umbilical Cord Blood: Biology and Transplantation
Am. Assoc. Cancer Res. Educ. Book,
April 1, 2006;
2006(1):
329 - 333.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Orfeo, S. Butenas, K. E. Brummel-Ziedins, and K. G. Mann
The Tissue Factor Requirement in Blood Coagulation
J. Biol. Chem.,
December 30, 2005;
280(52):
42887 - 42896.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. B. Louvain-Quintard, E. P. Bianchini, C. Calmel-Tareau, M. Tagzirt, and B. F. Le Bonniec
Thrombin-activable Factor X Re-establishes an Intrinsic Amplification in Tenase-deficient Plasmas
J. Biol. Chem.,
December 16, 2005;
280(50):
41352 - 41359.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Lane, H. Philippou, and J. A. Huntington
Directing thrombin
Blood,
October 15, 2005;
106(8):
2605 - 2612.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Butenas, B. A. Bouchard, K. E. Brummel-Ziedins, B. Parhami-Seren, and K. G. Mann
Tissue factor activity in whole blood
Blood,
April 1, 2005;
105(7):
2764 - 2770.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Kawasaki, N. Katori, M. Kodaka, H. Miyao, and K. A. Tanaka
Electron Microscopic Evaluations of Clot Morphology During Thrombelastography(R)
Anesth. Analg.,
November 1, 2004;
99(5):
1440 - 1444.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Tanaka, N. Katori, F. Szlam, N. Sato, A. B. Kelly, and J. H. Levy
Effects of tirofiban on haemostatic activation in vitro
Br. J. Anaesth.,
August 1, 2004;
93(2):
263 - 269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Butenas, T. Orfeo, M. T. Gissel, K. E. Brummel, and K. G. Mann
The Significance of Circulating Factor IXa in Blood
J. Biol. Chem.,
May 28, 2004;
279(22):
22875 - 22882.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Orfeo, N. Brufatto, M. E. Nesheim, H. Xu, S. Butenas, and K. G. Mann
The Factor V Activation Paradox
J. Biol. Chem.,
May 7, 2004;
279(19):
19580 - 19591.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. J. Chao, S. G. Emerson, and K. I. Weinberg
Stem Cell Transplantation (Cord Blood Transplants)
Hematology,
January 1, 2004;
2004(1):
354 - 371.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Kalafatis, D. O. Beck, and K. G. Mann
Structural Requirements for Expression of Factor Va Activity
J. Biol. Chem.,
August 29, 2003;
278(35):
33550 - 33561.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. L. Chandler and T. Velan
Estimating the rate of thrombin and fibrin generation in vivo during cardiopulmonary bypass
Blood,
June 1, 2003;
101(11):
4355 - 4362.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Mann, S. Butenas, and K. Brummel
The Dynamics of Thrombin Formation
Arterioscler Thromb Vasc Biol,
January 1, 2003;
23(1):
17 - 25.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Butenas, K. E. Brummel, S. G. Paradis, and K. G. Mann
Influence of Factor VIIa and Phospholipids on Coagulation in "Acquired" Hemophilia
Arterioscler Thromb Vasc Biol,
January 1, 2003;
23(1):
123 - 129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Schroeder, H. P. Kohler, K. E. Brummel, and K. G. Mann
Factor XIII activation by thrombin depends on FXIIIVal34Leu genotype
Blood,
January 1, 2003;
101(1):
371 - 371.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. G. Mann and M. Kalafatis
Factor V: a combination of Dr Jekyll and Mr Hyde
Blood,
January 1, 2003;
101(1):
20 - 30.
[Full Text]
[PDF]
|
 |
|
|
|